Daewoong Pharmaceutical announced on September 7 that it has obtained a patent for the treatment of migraine with botulinum toxin, NABOTA, in the United States. The patent was obtained through Daewoong's US partner AEON Biopharma, Inc.
AEON Biopharma was granted a patent for botulinum toxin ABP-450 (Korean name NABOTA) by the USPTO for "Neurotoxin Compositions for Use in Treating Headache".
The patent recognizes AEON Biopharma's ability to reduce the number of doses and change the location of administration compared to existing botulinum toxin formulations, which dramatically improves ease of use and reduces side effects. The patent protects exclusive rights in the U.S. until 2041.
Daewoong believes that the acquisition of NABOTA's migraine patent will support AEON Biopharma's ongoing Phase 2 clinical trials in the U.S. for the treatment of intermittent and chronic migraine.
Daewoong Pharmaceutical is targeting the global botulinum toxin market beyond Korea by focusing on highly marketable therapeutic indications. According to market research firm Fortune business insight, the global botulinum toxin market was valued at $6.5 billion last year, of which 53% is therapeutic and the rest is cosmetic.
Daewoong plans to expand the range of treatment indications, including intermittent migraine, chronic migraine, cervical dystonia, gastroparesis, and post-traumatic stress disorder (PTSD).
With this patent, which protects the exclusive use of NABOTA for these indications, Daewoong will be able to accelerate its entry into the botulinum toxin treatment market.
